Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bio-Nucleonics has resumed production of its cancer drug - Strontium Chloride Sr-89 Injection USP (Strontium-89).
Subscribe to our email newsletter
Strontium-89, an intravenously (IV) administered cancer drug, provides pain relief for patients suffering from bone pain due to metastatic cancer, caused by advanced stage breast, prostate or lung cancer.
Bio-Nucleonics claims Strontium-89, preferentially absorbed in bone metastases, provides a long-term effect resulting in an enhanced quality-of-life.
The company develops radiopharmaceuticals, medical devices and imaging agents for the detection and treatment of oncological, cardiovascular and neurological diseases.